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Abstract: As stroke care has developed, there has been a need to robustly assess the efficacy 
of interventions both at the level of the individual stroke survivor and in the context of clinical 
trials. To describe stroke-survivor recovery meaningfully, more sophisticated measures are 
required than simple dichotomous end points, such as mortality or stroke recurrence. As stroke 
is an exemplar disabling long-term condition, measures of function are well suited as outcome 
assessment. In this review, we will describe functional assessment scales in stroke, concentrating 
on three of the more commonly used tools: the National Institutes of Health Stroke Scale, the 
modified Rankin Scale, and the Barthel Index. We will discuss the strengths, limitations, and 
application of these scales and use the scales to highlight important properties that are relevant 
to all assessment tools. We will frame much of this discussion in the context of “clinimetric” 
analysis. As they are increasingly used to inform stroke-survivor assessments, we will also 
discuss some of the commonly used quality-of-life measures. A recurring theme when consider-
ing functional assessment is that no tool suits all situations. Clinicians and researchers should 
chose their assessment tool based on the question of interest and the evidence base around 
clinimetric properties.
Keywords: Barthel Index, clinimetrics, clinical trial, disability, methodology, modified Rankin 
Scale, National Institutes Health Stroke Scale, scales, stroke, outcomes
Why measure functional outcomes in stroke trials?
Large-scale clinical trials have created a robust evidence base to inform much of what 
is now standard acute-stroke practice.1–3 The classical clinical trial is designed to test 
efficacy of a particular intervention over a comparator, for example, placebo or “usual 
care.” To facilitate comparison between the groups requires a standard measure of 
outcome that is relevant and suited to the clinical question, valid for the population 
studied, and meaningful to the research team. In those trials that describe interven-
tions designed to impact on quantifiable physiological variables, such as glycemia or 
blood pressure, choice of end-point assessment is reasonably straightforward. Choice 
of assessment strategy is more challenging for a chronic, nonprogressive, or variably 
progressive disorder with potential multisystem effects such as cerebrovascular disease. 
“Hard” clinical end points such as stroke mortality or stroke recurrence are useful, 
but do not fully capture the potential devastating effect of a disabling but survivable 
stroke. As stroke represents the leading global cause of adult disability,4 an important 
consideration for any study of stroke interventions is functional recovery. This is 
recognized by regulatory authorities, who now recommend a measure of functional 
recovery/disability as primary or coprimary end point for stroke intervention trials.
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Although the focus of this review will be functional 
assessment tools for stroke trials, these instruments also 
have utility in clinical practice. As functional assessment 
scales give a numerical value to abstract concepts such as 
“disability,” they can be used to objectively quantify deficits 
and track change over time. This can be particularly useful 
in a rehabilitation setting. In clinical practice, an apprecia-
tion of how to describe stroke recovery in terms of common 
stroke scales allows for development of a common language 
between professionals caring for stroke survivors that facili-
tates comparisons of patients and services. Within a single 
review, it would be impossible to review all stroke-specific 
and generic scales that may be needed in a stroke survivor’s 
journey (Figure 1). For the interested reader, we recommend 
a number of reference works.5–7 We recognize there is also 
extensive literature on assessment strategies for cognitive 
function poststroke. We will not review cognitive testing, 
suffice to say that there are a multitude of tools available 
with little consistency in choice of assessment.8
Which functional measure to use
A large number of stroke-assessment scales are described, 
with novel scales frequently appearing (and often subse-
quently disappearing) in the literature. For those who are 
new to functional assessment, the large and varied nature of 
 available scales and tools may seem daunting. The World 
Health Organization’s International Classification of Func-
tioning, Disability and Health (WHO-ICF)9 gives a conceptual 
framework that can aid classification of the scales and help 
decide on the appropriate measure for a particular purpose.
WHO-ICF describes levels of pathology (in this case, the 
stroke lesion), impairments (the direct loss of function), activ-
ity limitation (formerly called disability), and societal partici-
pation (formerly called handicap). The WHO-ICF grades do 
not exist in isolation; they interact and often create feedback 
loops. For example, an ischemic stroke (pathology) may cause 
a hemianopia (impairment); this may lead to poor mobility 
(activity limitation) and may restrict the stroke survivor from 
driving (societal participation limitation). These problems may 
result in a fall with soft-tissue injury (impairment), and fear of 
falling may cause the stroke survivor to forgo usual hobbies 
and activities (societal participation limitation) (Figure 2).
Tools that assess stroke at all these levels are available. 
Measures of pathology (for example, size of infarct on imag-
ing) or impairment (for example the Medical Research Coun-
cil Motor Assessment Scale) are straightforward to perform 
and interpret, but give little useful information on how stroke 
affects the individual. For this reason,  impairment scales are 
Day 0 Patient assessed in ED with impairment scales: 
GCS, MRC powers scale and NIHSS; these guide decision to offer intravenous thrombolysis
Day 1 Further assessment with GCS and NIHSS to assess recovery/deterioration
Day 4 Nursing staff perform baseline assessments with Barthel
Index and Montreal Cognitive Assessment
Day 7 To inform discharge planning, the occupational 
therapy team assess  Nottingham E-ADL 
Day 40 Due to upper limb problems, response to 
physiotherpay is assessed with modified Ashworth Scale 
(spasticity) and Action Research Arm Test (function)
Day 30 Home visit, nurses perform global 
assessment with mRS
Day 90 Stroke survivor is assessed by clinical psychology using Hospital Anxiety 
and Depression Screen; Addenbrookes’ Cognitive Examination and Euro-QOL 
Day 120 Local driving assessment center performs assessment of visual impairment 
and stroke driver screening assessment battery  
Figure 1 Scales used at various points in the stroke survivor’s journey. 
Notes: Note how scale domains move from impairment to activity and participation as the subject progresses. Note also the various agencies that may use scales in their 
assessment.
Abbreviations: ED, emergency department; GCS, Glasgow Coma Scale; NIHSS, National Institutes of Health Stroke Scale; E-ADL, extended activities of daily living; 
mRS, modified Rankin Scale; QOL, quality of life; MRC, Medical Research Council.
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often used in early phase trials. For phase III studies, activity 
measures or measures of participation are usually preferred. 
Although not part of the WHO-ICF, a further concept of 
quality of life (QOL) is also described, and tools exist for 
its measurement. Measures of QOL give a far more detailed 
assessment, but as a result can be more burdensome to the 
patient and are often more difficult to interpret (Figure 3).
Clinimetric properties of scales
Clinimetrics is the study of properties of clinical assessment 
tools;10 the term is derived from the theory of psychometrics.11 
Classical test theory describes important properties such as 
validity and reliability.12 Other important factors for clinical 
scales are acceptability, both to patient and to assessor, and 
responsiveness to change. Although in psychometrics, classical 
test measures are increasingly being superseded by contempo-
rary theories of “item response,” the measures of validity, reli-
ability, and responsiveness remain important for understanding 
clinical scales, and we will discuss them in turn.
The clinimetric property of validity seeks to assess 
whether a scale measures the concept it purports to measure. 
Adequate validity is essential for a stroke scale to have 
clinical utility, as a functional assessment tool that does not 
measure function is meaningless. Validity can be assessed in 
various complementary ways.5–7 There is no “gold standard” 
for poststroke function, so assessment of criterion validity, 
where a scale is compared to a reference standard, is not 
 possible. However, concurrent validity can be applied to a 
stroke scale by comparing it with another measure that pur-
ports to measure a similar construct; for example, comparing 
a novel impairment scale with an established scale. Face 
validity is an assessment of whether a priori the scale should 
measure the concept of interest, usually assessed by experts 
in the field. Content validity asks whether the various items 
of a scale can adequately describe the concept of interest. 
Prognostic or predictive validity for a stroke scale may be 
examined by, for example, studying if an impairment scale 
is associated with longer-term stroke outcomes.
Impairment
Pathology
Activity Participation
Figure 2 World Health Organization international classification.
Quality of life
Participation
Activity
Impairment
Eg, National Institutes of
Health Stroke Scale
often used in acute-stroke 
studies and phase II trials
Eg, London Handicap Scale
often used in large scale 
definitive phase III
intervention trialsEg, Barthel Index of 
activities of daily living
often used in early phase 
rehabilitation studies
Eg, Euro-QOL
often used in longer-term 
follow-up and 
observational work 
Figure 3 Examples of commonly used stroke scales at differing levels of function.
Abbreviation: QOL, quality of life.
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Reliability is a measure of consistency in scoring. For 
stroke scales, important reliability measures include the 
reproducibility of repeat scoring by the same observer (intrao-
bserver reliability or test–retest reliability) and between 
scorers (interobserver variability). Whether all items within 
a scale measure the same construct is a further measure of 
reliability, usually termed internal consistency. In contempo-
rary stroke trials, where many thousands of stroke survivors 
may be assessed by hundreds of international research teams, 
reliability of assessment is clearly paramount. Whereas 
validity of a scale is inherent, reliability of assessment may 
be  modified. Various methods to improve consistency of 
assessment are employed in large-scale trials, including 
training in use of scales, certification exams, and use of 
standardized protocols. While validity is relative, reliability 
can be objectively described. There is no consensus on the 
optimal method to measure reliability, although kappa statis-
tics are frequently used in the biomedical literature to assess 
 agreement. Kappa statistics quantify agreement above that 
which would be expected by chance. A kappa of 0 would 
imply no agreement other than that expected by chance, and 
perfect agreement is scored as 1.0. Traditionally, a kappa 
greater than 0.6 is taken as sufficient agreement to justify use 
of a scale. Various forms of statistical “weighting” of kappa 
values can be used to give a measure of the degree of dif-
ference between raters.13,14 Increasingly, more sophisticated 
analyses, such as that of Bland–Altman, are being used to 
assess reliability.15
Responsiveness can be thought of as the ability to detect 
meaningful change over time. Meaningful change is clearly a 
subjective term, and will vary with the context in which the 
scale is used. The issue of responsiveness and the ability to 
detect small but meaningful change is especially important 
for a condition with high incidence and prevalence, such as 
stroke. If a scale does not pick up change in function, treat-
ment effects that are modest for the individual but potentially 
important at a population level could be missed.
The ideal scale would be easy and quick to administer, 
acceptable to patients and researchers, valid for its chosen 
purpose, reliable, and responsive to meaningful clinical 
change. There is no ideal stroke measure that fulfills all 
these criteria (nor is there ever likely to be). Although some 
guidance on stroke assessment for trials is emerging, debate 
continues as to the relative strengths and limitations of dif-
fering assessment strategies, and there is no consensus as to 
the optimal outcome measure(s) for use.
The stroke literature describes a variety of instruments, 
generic and specific to stroke, for functional assessment 
of recovery. A recent analysis of tools used in stroke trials 
suggests substantial heterogeneity in choice of assessment 
measure and in method of application.16 Use of bespoke, 
nonvalidated assessments is still seen, although less com-
monly than previously. Certain assessments are used more 
frequently than others and are increasingly recommended by 
specialist societies.17 For the non-stroke specialist, a basic 
knowledge of the more prevalent stroke scales will allow 
for improved understanding and critical analysis of stroke 
studies. We will describe three common stroke assessments: 
the National Institutes of Health Stroke Scale (NIHSS), the 
modified Rankin Scale (mRS) and the Barthel Index (BI). We 
will also discuss some of the commonly used QOL scales. 
For each scale, we will discuss history, development, and 
application, and use the scales to further discuss the impor-
tance of clinimetric properties.
The scientific study of assessment scales, particularly 
stroke assessment, is rapidly expanding and it would be 
impossible to comprehensively cover all areas. In this review, 
we will not describe the optimal analysis of functional scales 
for stroke trials. Debate continues as to the relative merits 
of various statistical techniques, including dichotomization 
and use of the complete range of a scale, with the differing 
approaches having vocal proponents.18,19 Equally, we will 
not consider the literature on outcome assessment in animal 
models of stroke.20,21
National Institutes of Health  
Stroke Scale
The NIHSS is a 15-item scale that standardizes and quanti-
fies the basic neurological examination, paying particular 
attention to those aspects most pertinent to stroke. The 
NIHSS provides an ordinal, nonlinear measure of acute 
stroke-related impairments by assigning numerical values 
to various aspects of neurological function.22 The scale 
incorporates assessment of language, motor function, sensory 
loss, consciousness, visual fields, extraocular movements, 
coordination, neglect, and speech.22 It is scored from 0 (no 
impairment) to a maximum of 42. Scores of 21 or greater 
are usually described as “severe.” A standardized approach 
to assessment, starting with fundamental assessments such 
as level of consciousness, is recommended, and guidance is 
given on how to score where the stroke survivor is not able 
to respond to commands.
The NIHSS was developed in the early 1980s as a 
research tool to allow consistent reporting of neurological 
deficits in acute-stroke studies, particularly the early trials of 
thrombolysis and putative neuroprotectants.22 The NIHSS was 
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developed through a robust consensus approach, taking the 
most informative measures from existent stroke-examination 
scales (Toronto Stroke Scale, Oxbury Initial Severity Scale, 
and Cincinnati Stroke Scale) and creating a composite scale 
that was further reviewed by a panel of stroke researchers and 
amended (further items were added to ensure the assessment 
was as comprehensive as possible). The resulting scale was 
piloted and refined in a controlled trial of naloxone in acute 
stroke. It has since been used as primary or coprimary end 
point in landmark trials of thrombolytic agents and is com-
monly used in clinical acute-stroke practice.
Using a factor-analysis process, utility of individual 
components of the NIHSS has been assessed.23 This work has 
formed the basis for development of the modified NIHSS or 
mNIHSS, which removed components deemed unreliable.24 
The resulting 11-point mNIHSS has been prospectively 
assessed, and improved reliability is described.25 As the stan-
dard NIHSS is already fairly quick to perform and reliable, 
it is debatable whether a shorter scale is needed, and at pres-
ent the mNIHSS is not frequently used in trials or practice. 
Further amendments to the NIHSS have been described to 
facilitate use of the scale in prehospital settings.26 A pediatric 
NIHSS (pedNIHSS) is also described.27
The NIHSS has many advantages as a stroke outcome-
assessment tool. It is relatively straightforward and takes 
around 6 minutes to perform, with no need for additional 
equipment. In the acute-stroke environment, the NIHSS 
is well suited to serial measures of impairment. It has 
been suggested that a change in the NIHSS of more than 
2 points represents clinically relevant early improvement 
or deterioration.28
NIHSS scores are reliable across observers, and this has 
been demonstrated both in cohorts of neurology-trained and 
non-neurologist raters. The availability of a reliable method 
for neurological exam that is suitable for nonspecialists is 
a particular strength of the NIHSS. Reliability and validity 
has also been demonstrated for remote NIHSS assessment 
via telemedicine.29 The interobserver reliability of the 
NIHSS is further improved by the various training materi-
als available. Training resources now exist, such as DVDs 
and online educational aids, as well as pocket-sized NIHSS 
summary scales. Practitioners can undergo certification to 
demonstrate their proficiency in assessment and interpreta-
tion of the NIHSS.30
Content validity of the NIHSS has been demonstrated, 
although high internal consistency suggests that certain items 
of the NIHSS may be redundant. The NIHSS has predictive 
validity, as initial score is a robust predictor of in-hospital 
complication and outcome at 3 months.31,32 Correlations with 
objective measures of stroke severity, such as size of infarct 
on imaging, provide further evidence of NIHSS validity.23,33,34 
Compared with BI and mRS, the NIHSS is the more sensitive 
outcome score, requiring potentially smaller sample sizes to 
detect relevant therapeutic effects.23,35 The NIHSS is respon-
sive to change and can measure impairment throughout the 
expected range of stroke severity.36
A criticism of the NIHSS relates to its validity in cer-
tain nondominant-hemisphere stroke syndromes. It is well 
recognized that an individual can score 0 on the NIHSS, 
despite having evidence of ischemic stroke, particularly 
in the  posterior circulation territory.37 Examination of the 
component subscales of the NIHSS reveals a focus on limb 
and speech impairments and relatively little attention to, for 
example, cranial nerve lesions. Similarly, when the NIHSS is 
used to predict dependent living, lower scores are seen in pos-
terior circulation events compared to anterior  circulation.38 
There are radiological correlates, when quantifying extent 
of cerebral damage for a specified NIHSS score, the median 
volume of right-hemisphere strokes is larger than the volume 
of left-hemisphere strokes, suggesting nondominant strokes 
are required to be more severe to reach the same grading on 
the NIHSS.39 As an impairment scale, the NIHSS can give 
only limited information on how stroke has affected the 
individual stroke survivor. For example, an NIHSS score 
of 1 is considered an “excellent” outcome from stroke; a 
hemianopia that precludes driving and may necessitate loss 
of employment would score NIHSS 1, but for the individual 
this may not seem an “excellent” result.
Barthel Index
Adapted from the Maryland Disability Index, the BI 
authors – Florence I Mahoney and Dorothea W Barthel – 
intended their scale for use as “a simple index of indepen-
dence, useful in scoring improvement in rehabilitation.”40 
First described in the 1950s and published in 1965, the BI 
was developed to assist in discharge planning from long-
term care wards. With time, the BI has been adopted by 
other disciplines and is a recommended assessment in older 
adult care.41 The BI is the most commonly used functional 
measure in stroke-rehabilitation settings and the second most 
commonly used functional outcome measure across stroke 
trials.16,42 Many scales have been described that take the 
name “Barthel Index”. Some authors have sought to modify 
or adapt the BI from the original; these include reducing the 
number of items,43 extending it with the addition of cogni-
tive and social domains,44 and attempts to further subdivide 
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the outcomes to include different degrees of assistance.45 
However, each of these requires independent validation, 
as it is known that even comparatively minor adaptations 
alter the validity of a tool and accuracy of responses.46 For 
consistency, it is recommended that a single BI measure is 
used; the scale as described by Wade and Collin47 has been 
used in many trials.
The BI assesses ten functional tasks of daily living (activi-
ties of daily living – ADL), scoring the individual depend-
ing on independence in each task. Scores range from 0 and 
100, with a higher score indicating greater independence 
(Table 1). The BI is usually summed to give a total score. 
While this can be useful for statistical analysis, it is more 
informative in practice to present the scores for the individual 
domains. An unresolved issue for trials is how to define a 
“good” BI outcome, with significant heterogeneity within the 
published literature48 and attempts to subcategorize, based 
on total score.49,50 A popular interpretation of BI scores is 
that subjects with BI . 80 are generally independent and 
should be able to return home; while subjects with BI , 40 
are very dependent.51 Other interpretations of favorable and 
unfavorable BI outcomes have been described: statistical 
modeling looking at differing BI scores as a trial end point 
suggested a score of 95/100 was the optimal descriptor of 
an excellent outcome and that 75/100 was the best cut point 
for defining a poor outcome.52
Validity of BI is well described. The scale is recognized 
as a valid prognostic tool following stroke, in particular as 
predictor of recovery, level of care required,53 and duration of 
rehabilitation required following stroke.54 BI scores correlate 
with other stroke-assessment scales,55 including other more 
detailed ADL scales.56 Interobserver reliability is usually 
quoted as a strength of the BI, and reliability has been dem-
onstrated in nonstroke populations.57 Systematic review of 
reliability of BI in stroke also suggests reasonable reliability, 
although few multicenter reliability studies are available.58
The original BI is not without its limitations. As a scale 
of primarily physical function, it does not reflect the burden 
on the individual of communication and cognitive deficits 
that can result from a stroke event.59 For clinical trials, the 
BI lacks a result to represent stroke mortality, and this can 
complicate analysis of results. However, the major limita-
tion of the BI for clinical trial use is its responsiveness to 
change. Although in certain stroke-care settings, the BI is as 
sensitive to change as other scales,60 a score must be able to 
represent changes throughout the entire spectrum of potential 
functional outcomes. It is in this regard that the “floor” and 
“ceiling” effects of the BI become apparent.50 “Floor and 
ceiling” describes the phenomenon by which the score does 
not change from minimum or maximum despite clinical 
change.61 For example, a stroke patient in a neurointensive 
care setting can make significant gains but still score a total 
0 on the BI; conversely, a patient who is discharged from 
hospital and independent may still have substantial functional 
problems but will score 100 on the BI. Given this limita-
tion, the BI may be best suited to stroke survivors requiring 
inpatient rehabilitation, while other scales may be needed to 
assess functional change in those with more major or minor 
stroke symptoms.62
The BI can be considered as a measure of “basic” ADL 
(self-care and mobility). Scales have been developed to 
encapsulate performance in more complex tasks. These are 
variously described as “instrumental” or “extended” activities 
of daily living (E-ADL) measures.63 The term “instrumental 
ADL” was first used in Lawton and Brody’s work, and a 
Lawton I-ADL scale is described.64 A validated measure 
that has been used with stroke survivors is the Nottingham 
Extended ADL Scale, which asks participants to reflect their 
Table 1 The Barthel Index of activities of daily living 
Domain assessed Score
0 5 10 15
Feeding Unable Requires assistance Independent  
Bathing Dependent Independent   
Grooming Needs help Independent   
Dressing Dependent Needs some help Independent  
Bowels Incontinent Occasional accident Continent  
Bladder Incontinent or catheterized Occasional accident Continent  
Toilet use Dependent Needs some help Independent  
Transfers (bed to chair and back) Unable Major help Minor help Independent
Mobility (on level surface) Immobile Wheelchair independent .  
50 yards
Walks with help of one Independent
Stairs Unable Needs help Independent  
Note: The wording and scoring presented is that of Wade and Collin.47
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actual activities over the preceding weeks, rather than simply 
what they have the capability to do.65,66 The Nottingham 
Extended ADL Scale compares favorably to the BI, and is 
less susceptible to the ceiling effects described.67
Modified Rankin Scale
The mRS is a 6-point, ordinal hierarchical scale that describes 
“global disability” with a focus on mobility (Table 2). The 
original Rankin Scale was developed by the Scottish physi-
cian John Rankin to describe the positive outcomes he was 
achieving in his prototypic stroke unit.68 Although not origi-
nally intended as an assessment for clinical trials, a slightly 
modified version of Rankin’s eponymous scale was used as 
end point in the first multicenter stroke trial (the UK TIA 
study).69 Since this time, the mRS has grown in popularity 
and is now the most commonly used functional measure in 
stroke trials, and has been the primary or coprimary outcome 
in most recent large-scale stroke trials.16 A further variation 
of the mRS, the Oxford Handicap Scale, has been described 
but is not commonly used by trialists. In contemporary 
stroke studies, the mRS is often used both as a measure of 
premorbid ability to assist in selection of patients and as final 
outcome measure.
The mRS has many potential strengths, and it is accept-
able to patient and assessor, with nonstandardized interviews 
taking around 5 minutes to complete.70 Concurrent validity is 
demonstrated by strong correlation with measures of stroke 
pathology (for example, infarct volumes) and agreement with 
other stroke scales.71,72 The six potential scores on the mRS 
(0–5) describe a full range of stroke outcomes, with a score 
of 6 usually added to denote death. With a limited number 
of scores, the mRS may be less responsive to change than 
some other scales; however, a single-point change on the 
mRS will always be clinically relevant.
The principle limitation of the mRS is its reliability, with 
the potential for substantial interobserver variability. A study 
describing the interobserver variability of the mRS is avail-
able; indeed, in the first clinical studies that used the mRS 
as end point, the trialists described interobserver variability 
for a third of subjects interviewed by paired assessors.73 
A systematic review and meta-analysis of studies describ-
ing interobserver variability of the mRS reports pooled 
reliability across ten published studies (n = 587 patients) of 
kappa = 0.46.74 Those studies that assessed mRS reliability 
with multiple raters and centers (ie, similar to a contempo-
rary clinical trial) revealed a worryingly low agreement of 
kappa = 0.21.75 This level of inconsistency will impact on 
the validity of the trial results and conclusions. The statistical 
“noise” created by the interobserver variability will increase 
the possibility of a type II error, ie, a beneficial treatment 
effect is missed. It has been postulated that problems with 
mRS reliability may have partly explained a series of unex-
pected neutral results in large-scale neuroprotectant studies. 
There are published examples of nonstroke studies whose 
results were fundamentally altered when statistical analysis 
accounted for observer variation.76
Recognizing the problems of reliability in standard mRS 
assessments, trialists have explored various interventions 
to improve consistency in scoring. Usual mRS interviews 
are unstructured, and researchers vary considerably in their 
length of interview and number of questions asked. More 
structured approaches to assessment have been described, 
from a comprehensive scripted interview75 to use of anchor-
ing questions that require a yes/no answer.77 The groups that 
developed these assessments describe substantial improve-
ments in reliability. However, improvements have not been 
seen when the structured interviews have been tested by 
independent centers.78 Training in use of the mRS can also 
offer potential to improve consistency. As with the NIHSS 
and BI, an online training resource is available with an 
accompanying certification exam.79 A further trial modifica-
tion that may improve reliability is to record mRS interviews 
and have a remote consensus grading by experienced stroke 
trialists. This approach is currently being utilized by a number 
of multicenter studies.
Two other modifications to mRS assessment are com-
monly used and deserve some discussion: using proxies 
to substitute for stroke survivors in the mRS interview 
and calculating a “prestroke” mRS. Stroke survivors often 
have physical, language, or cognitive impairments that may 
Table 2 The modified Rankin Scale (mRS)
Grade 0 No symptoms at all
Grade 1 No significant disability despite symptoms; able 
to carry out all usual duties and activities
Grade 2 Slight disability; unable to carry out all previous 
activities, but able to look after own affairs 
without assistance
Grade 3 Moderate disability; requiring some help, but able 
to walk without assistance
Grade 4 Moderately severe disability; unable to walk 
without assistance, unable to attend to needs 
without assistance
Grade 5 Severe disability; bedridden, incontinent, and 
requiring constant nursing care and attention
Grade 6 Dead
Notes: The grade of mRS 6 was added for clinical trial purposes and was not part 
of the original scale.
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 complicate a standard face-to-face interview. In this situation, 
an informant who knows the patient often supplements the 
interview or substitutes it completely. While this approach 
makes intuitive sense, we should not assume validity, and 
clinimetric analysis is still required. A recent systematic 
review of proxy stroke scales (the mRS was not included) 
suggested that the properties of certain proxy-based assess-
ments may differ from equivalent standard assessments.80 
A study of proxy mRS described suboptimal reliability and 
validity, and recommended that direct mRS interview with 
the patient should be the preferred assessment if possible.81 
In stroke trials, traditional statistical analyses assess num-
bers achieving a “good” functional outcome. To improve 
trial power, subjects with disability prior to the stroke event 
are often excluded. Assessment of a “prestroke mRS” has 
been used in many landmark stroke trials, where prestroke 
mRS . 2 is used as the exclusion criterion during participant 
selection. The wording of the mRS grades is not suited to 
such prestroke assessment, and it is perhaps unsurprising that 
when formally assessed, prestroke mRS had only moderate 
reliability and validity.82
Quality of life
In view of improving longer-term survival and functional 
outcomes following stroke,83 it could be argued that assess-
ments against participation or QOL will become increasingly 
important.84 Certainly evaluations of health-related QOL in 
stroke survivors can provide a rich description of the mul-
tifaceted effects of a stroke, providing insights above those 
recorded with traditional impairment and activity measures.85 
Measuring health-related QOL in stroke presents particular 
challenges. Important predictors and components of QOL 
following stroke will vary at different periods following the 
event.86 Thus, we must balance having a suitably compre-
hensive assessment that is sensitive to the nuances of QOL 
against the time and burden required for this assessment. 
QOL is very much dependent on the individual’s experience 
of their condition. This poses a particular problem where the 
stroke survivor has difficulty communicating. Carer/family-
based assessments of the patient’s QOL are often biased, with 
the proxies reporting poorer outcomes than the subject.87
Various QOL scales have been proposed, some generic 
and some specific to stroke/brain injury. QOL scales should 
be subject to the same rigor of clinimetric assessment as any 
other scale. It is evident from the published literature that 
for QOL there is a propensity to generate new scales rather 
than validating existing ones.88,89 It has been argued that 
QOL can be assessed by asking just two questions assessing 
“dependency” and “problems.”90 An alternative approach 
is to apply existing health-related QOL scales or to use 
disease-specific scores. There are strengths and limitations 
to each approach.
The Short Form 36 (SF-36) is a generic scale intended 
for patient completion that assesses eight domains of 
health-related QOL derived from the Medical Outcomes 
Study (Table 3).91 Although the SF-36 is validated for stroke 
patients,92 noncompletion bias and marked floor and ceil-
ing effects may limit its utility.93,94 The generic QOL scale, 
 Euro-Qol, was developed based on the findings of an inter-
national postal survey.95 The self-completion questionnaire 
requires assessment across five domains complemented by 
a visual analog scale (Table 3).96 EuroQol has been validated 
in stroke populations.97 However, noncompletion bias is 
recognized: in one study, only 61% of stroke survivors could 
complete the scale without external assistance.97 The stroke-
specific QOL scale was developed based on interviews with 
stroke survivors.98 It is based on twelve domains (Table 3).93 
The scale is validated in stroke populations, and values for 
“minimal detectable change” and “clinically important dif-
ference”99 are established. A modification for those with 
poststroke aphasia is also described.100
Conclusion
Many assessment tools, spanning various functional domains, 
are available to clinicians and researchers working with 
stroke survivors. We have given a flavor of the marked het-
erogeneity in use of assessment scales. Lack of consistency 
Table 3 Domains assessed in three commonly used quality-of-
life scales 
Scale
SF-36 Euro-Qol SS-QOL
Domains
Physical functioning Mobility Mobility
Physical role limitations Self-care Self-care
Emotional role limitations Anxiety/depression Mood
Emotional well-being Usual activities Work/productivity
Social functioning Pain/discomfort Social roles
Bodily pain Family roles
General health Language
vitality Personality
Energy
Thinking
Upper extremity 
function
vision
Note: Differences in content and scope for three scales that purport to measure 
the same construct.
Abbreviations: SF-36, Short Form 36; SS-QOL, stroke-specific quality of life; 
QOL, quality of life.
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in outcome assessment has hindered comparative research 
and meta-analysis, and so we would recommend that future 
researchers use a common set of outcome assessments. No 
perfect stroke-assessment scale exists, and in this review 
we have deliberately avoided suggestions that one scale is 
better than an other. We have focused on the three most com-
monly used stroke scales (mRS, BI, NIHSS) as exemplars. 
These scales have been validated, are familiar to many, and 
have proven utility, with each suited to differing assessment 
scenarios. Thus, in the absence of a “perfect” assessment, 
we would recommend continuing use of the three core 
assessment scales: the mRS as an outcome if the study is 
describing global disability, the NIHSS for studies looking 
at neurological impairment, and the BI for studies looking 
at basic ADL. Trialists and clinicians can supplement these 
core assessments with specific tools suited to the clinical 
scenario/research question. Increasing awareness of the 
importance of clinimetric properties has highlighted defi-
ciencies and potential limitations with stroke functional 
assessment.  Clinicians and researchers should always select 
their assessment tool(s) based on the question of interest and 
the evidence base around clinimetric properties. Where, as is 
often the case, the research around clinimetric properties of 
a scale is sparse, we would encourage researchers to design 
and conduct their own clinimetric studies.
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